Infliximab in rheumatic diseases
Loading...
Date
Authors
Janse van Rensburg, Dina Christina
Journal Title
Journal ISSN
Volume Title
Publisher
Media 24
Abstract
Infliximab (REVELLEX®) is a chimeric IgG1κ monoclonal antibody against tumor necrosis factor-α
(TNF-α). Infliximab is indicated, for the treatment of rheumatoid arthritis (RA), ankylosing
spondylitis (AS), psoriatic arthritis (PsA), Crohn’s disease (CD, ulcerative colitis (UC) and skin
psoriasis.
The first aim of this article is to revisit the indications for the use of Infliximab in RA, AS and PsA.
The second aim is to get an update on the newest insights on the safety and efficacy of the drug.
Description
In this article no comparison with regards to long-term efficacy and safety was made to other
biologic drugs.
Keywords
Infliximab, Tumor, Treatment, Rheumatoid arthritis
Sustainable Development Goals
Citation
Janse van Rensburg, DC 2013, 'Infliximab in rheumatic diseases', South African Rheumatology Journal, vol. 5, no. 2, pp. 21-24.